RT Journal Article
T1 Heterogeneity in Response to MCT and Psychoeducation: A Feasibility Study Using Latent Class Mixed Models in First-Episode Psychosis.
A1 Ferrer-Quintero, Marta
A1 Fernandez, Daniel
A1 Lopez-Carrilero, Raquel
A1 Diaz-Cutraro, Luciana
A1 Verdaguer-Rodriguez, Marina
A1 Garcia-Mieres, Helena
A1 Huerta-Ramos, Elena
A1 Gomez-Benito, Juana
A1 Pelaez, Trini
A1 Birules, Irene
A1 Barajas, Ana
A1 Pousa, Esther
A1 Barrigon, Marisa
A1 Gutierrez-Zotes, Alfonso
A1 Grasa, Eva
A1 Ruiz-Delgado, Isabel
A1 Lorente-Rovira, Esther
A1 Cid, Jordi
A1 Ochoa, Susana
K1 First-episode psychosis
K1 Latent class mixed models
K1 Metacognition
K1 Metacognitive training
K1 Psychoeducation
K1 Social cognition
AB Metacognitive training (MCT) is an effective treatment for psychosis. Longitudinal trajectories of treatment response are unknown but could point to strategies to maximize treatment efficacy during the first episodes. This work aims to explore the possible benefit of using latent class mixed models (LCMMs) to understand how treatment response differs between metacognitive training and psychoeducation. We conducted LCMMs in 28 patients that received MCT and 34 patients that received psychoeducation. We found that MCT is effective in improving cognitive insight in all patients but that these effects wane at follow-up. In contrast, psychoeducation does not improve cognitive insight, and may increase self-certainty in a group of patients. These results suggest that LCMMs are valuable tools that can aid in treatment prescription and in predicting response to specific treatments.
PB MDPI
SN 2227-9032
YR 2022
FD 2022-10-28
LK http://hdl.handle.net/10668/21007
UL http://hdl.handle.net/10668/21007
LA en
NO Ferrer-Quintero M, Fernández D, López-Carrilero R, Díaz-Cutraro L, Verdaguer-Rodríguez M, García-Mieres H, et al. Heterogeneity in Response to MCT and Psychoeducation: A Feasibility Study Using Latent Class Mixed Models in First-Episode Psychosis. Healthcare (Basel). 2022 Oct 28;10(11):2155
NO This study was funded by the Instituto de Salud Carlos III, Spanish Government (PI11/01347, PI14/00044, and PI18/00212); the Fondo Europeo de Desarrollo Regional (FEDER), Health Department of Catalonia, PERIS call (SLT006/17/00231); Progress and Health Foundation of the Andalusian Regional Ministry of Health (PI-0634/2011 and PI-0193/2014); Obra Social La Caixa (RecerCaixa call 2013), Obra Social Sant Joan de Déu, BML (RTI2018-100927-J-I00) administered by Ministerio de Ciencia e Innovación (MCI, Spain), by the Agencia Estatal de Investigación (AEI, Spain), and by the European Regional Development Fund (FEDER, EU); Daniel Fernández has been supported by grant 2017 SGR 622 (GRBIO) administered by the Departament d’Economia i Coneixement de la Generalitat de Catalunya (Spain) and by the Ministerio de Ciencia e Innovación (Spain) [PID2019104830RB-I00/ DOI (AEI): 10.13039/501100011033]; and CIBER, Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
DS RISalud
RD Apr 8, 2025